Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $284 to $272.
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $284 to $272.